Merck, Ra Pharma enter drug-development deal worth up to $200M

04/2/2013 | Pharmaceutical Business Review Online · Xconomy

Merck and Ra Pharmaceuticals agreed to collaborate in the development of Cyclomimetics drug candidates against multiple therapeutic areas using the latter's Extreme Diversity platform. Cyclomimetics are peptidelike molecules that have the diversity and specificity of antibodies. The deal entitles Ra to about $200 million in payments including upfront fee, research funding and milestone fees.

View Full Article in:

Pharmaceutical Business Review Online · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ